de Boer Ian H, Sibley Shalamar D, Kestenbaum Bryan, Sampson Joshua N, Young Bessie, Cleary Patricia A, Steffes Michael W, Weiss Noel S, Brunzell John D
Division of Nephrology, University of Washington, Seattle, Washington 98195, USA.
J Am Soc Nephrol. 2007 Jan;18(1):235-43. doi: 10.1681/ASN.2006040394. Epub 2006 Dec 6.
Weight gain and central obesity are associated with insulin resistance, hypertension, and dyslipidemia in type 1 diabetes. These metabolic abnormalities are risk factors for kidney disease in the general population, but data addressing the relationship of central obesity with kidney disease in type 1 diabetes are limited. Whether waist circumference is associated with incident microalbuminuria and change in creatinine clearance was examined among 1279 participants who had type 1 diabetes and were enrolled in the Epidemiology of Diabetes Interventions and Complications Study, the observational extension of the Diabetes Control and Complications Trial (DCCT). Ninety-three of 1105 participants with normal albumin excretion rate (AER) at DCCT closeout developed incident microalbuminuria over 5.8 yr of follow-up. The hazard ratio for incident microalbuminuria that was associated with each 10-cm greater waist circumference at DCCT closeout was 1.34 (95% confidence interval 1.07 to 1.68), after adjustment for DCCT closeout age, gender, duration of diabetes, treatment group, smoking status, glycosylated hemoglobin, and AER. This increased risk was modestly attenuated when additional adjustment was made for levels of BP and serum lipids. Creatinine clearance declined by an average of 0.34 ml/min per 1.73 m2 each yr over 8 yr of follow-up. Greater rate of decline in creatinine clearance was associated with greater age, conventional insulin therapy during the DCCT, smoking, and greater glycosylated hemoglobin and AER at DCCT closeout but not with waist circumference. In conclusion, waist circumference predicts the subsequent development of microalbuminuria in type 1 diabetes. In contrast, no association of waist circumference with decline in creatinine clearance was observed.
在1型糖尿病中,体重增加和中心性肥胖与胰岛素抵抗、高血压及血脂异常相关。这些代谢异常是普通人群中肾脏疾病的危险因素,但关于1型糖尿病中中心性肥胖与肾脏疾病关系的数据有限。在1279名1型糖尿病患者中进行了研究,这些患者参与了糖尿病干预与并发症流行病学研究(Diabetes Control and Complications Trial, DCCT的观察性扩展研究),以探讨腰围是否与微量白蛋白尿的发生及肌酐清除率的变化相关。在DCCT结束时白蛋白排泄率(AER)正常的1105名参与者中,有93人在5.8年的随访中出现了微量白蛋白尿。在对DCCT结束时的年龄、性别、糖尿病病程、治疗组、吸烟状况、糖化血红蛋白和AER进行调整后,DCCT结束时腰围每增加10厘米,发生微量白蛋白尿的风险比为1.34(95%置信区间为1.07至1.68)。当对血压和血脂水平进行额外调整时,这种增加的风险略有降低。在8年的随访中,肌酐清除率平均每年每1.73 m²下降0.34 ml/min。肌酐清除率下降速度更快与年龄较大、DCCT期间采用传统胰岛素治疗、吸烟以及DCCT结束时糖化血红蛋白和AER较高有关,但与腰围无关。总之,腰围可预测1型糖尿病患者随后发生微量白蛋白尿。相比之下,未观察到腰围与肌酐清除率下降之间存在关联。